Cas:537678-10-7 3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine manufacturer & supplier

We serve Chemical Name:3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine CAS:537678-10-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine

Chemical Name:3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine
CAS.NO:537678-10-7
Synonyms:3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine
Molecular Formula:C16H15Cl2NO2S2
Molecular Weight:388.33200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:71.06000
Exact Mass:386.99200
LogP:5.75680

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine Use and application,3-[(3,4-Dichlorophenyl)sulfonyl]-2-(4-methylphenyl)-1,3-thiazolid ine technical grade,usp/ep/jp grade.


Related News: AstraZeneca acquired global rights to anifrolumab through an exclusive license and collaboration agreement with Medarex, Inc. in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. N,N’-bis-(2,4-dimethyl-phenyl)-N’-phenyl-N,N’-di-p-tolyl-[1,3,5]triazine-2,4,6-triamine manufacturers For its part, the FDA’s representative at the meeting, Doran Fink, M.D., said the drug regulator is “working as rapidly as possible to conduct a thorough and comprehensive” review of all the COVID-19 vaccines that have applied for full approval. Pfizer and Moderna recently submitted their applications for a full nod. (2S,3R,5R,9R,10R,13R,14S,17S)-10,13-Dimethyl-17-((1R,2R)-1,2,5-trihydroxy-1,5-dimethyl-hexyl)-1,2,3,4,5,6,9,10,11,12,13,15,16,17-tetradecahydro-cyclopenta[a]phenanthrene-2,3,6,14-tetraol suppliers “We’re going to further invest in research and development to continue to build our pipeline of products, in a more sophisticated way,” he says, holding up a pocket-sized wearable device and a tiny insulin pen to his screen’s camera. “We really believe in this business for the next—we hope—70 years.” 1-oxyl-4-(2-thienyl)-2,2,5,5-tetramethyl-3-imidazoline 3-oxide vendor & factory.